Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Jul 2012 14:47

RNS Number : 2855I
Fastnet Oil & Gas PLC
23 July 2012
 



 

 

Standard Form TR-1Voting rights attached to shares- Article 12(1) of directive 2004/109/ECFinancial instruments - Article 11(3) of the Commission Directive 2007/14/EC[i]

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached [ii]:

 

Fastnet Oil and Gas

 

2. Reason for the notification (please tick the appropriate box or boxes):

[x ] an acquisition or disposal of voting rights

[ ] an acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

[ ] an event changing the breakdown of voting rights

3. Full name of person(s) subject to the notification obligation[iii]:

J&E Davy T/A Davy

 

4. Full name of shareholder(s) (if different from 3.)[iv]:

 

5. Date of the transaction and date on which the threshold is crossed or reached[v]:

20 July 2012

 

6. Date on which issuer notified;

23 July 2012

 

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details:

 

1.

1. 1. 1.

A) Voting rights attached to shares

Class/type of shares (if possible using the ISIN CODE)

Situation previous to the Triggering transaction [vi]

Resulting situation after the triggering transaction[vii]

Number of Shares[viii]

Number of Voting rights[ix]

Number of shares[x]

Number of voting rights[xi]

% of voting rights

Direct

Direct[xii]

Indirect[xiii]

Direct

Indirect

GB00B85HRF56

Below 3%

4,485,538

 

 

4,485,538

 

2.72%

SUBTOTAL A (based on aggregate voting rights)

Below 3%

4,485,538

 

4,485,538

 

2.72%

 

B) Financial Instruments

Resulting situation after the triggering transaction[xiv]

Type of financial instrument

Expiration Date[xv]

Exercise/Conversion Period/ Date[xvi]

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

SUBTOTAL B (in relation to all expiration dates)

 

Total (A+B)

number of voting rights

% of voting rights

4,485,538

 

2.72%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instrumentsare effectively held, if applicable[xvii]:

10. In case of proxy voting:[name of the proxy holder] will cease to hold [number] voting rights as of [date].

11. Additional information:

Done at [place] on [date].

 


[i] This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority.

 

[ii] Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.

 

[iii] This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC; (c) all the parties to the agreement referred to in Article 10 (a) of that Directive, or (d) the holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of that Directive, the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive, the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive, the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive, the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive, the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9, under letters (a) to (d) of Article 10 of that Directive or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive, the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive, the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive, the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion.

[iv] Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC. This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive unless the holdings of the shareholder would be lower than 5% of the total number of voting rights.

 

[v] The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. 

 

The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect. For passive crossings, the date when the corporate event took effect.

 

[vi] Please refer to the situation disclosed in the previous notification. In case the situation previous to the triggering transaction was below 3%, please state "below 3%".

 

[vii] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

For the case provided for in Article 10(a) of Directive 2004/109/EC, there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement.

 

[viii] To be used in Member States where applicable.

 

[ix] Direct and indirect.

 

[x] To be used in Member States where applicable.

 

[xi] In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

[xii] Voting rights attached to shares held by the notifying party (Article 9 of Directive 2004/109/EC).

 

[xiii] Voting rights held by the notifying party independently of any holding of shares (Article 10 of Directive 2004/109/EC).

 

[xiv] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

[xv] Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

[xvi] If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

[xvii] The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 3% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGUACMUPPGWW
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.